Liver Transplant News and Research

RSS

When a patient presents with end stage liver disease or liver failure he or she may be considered for a liver transplantation. The first step in this is often a rigorous assessment and being placed on a waiting list.

Researchers introduce new class of drugs for HCV patients

To improve the care for individuals infected with the hepatitis C virus, a major health problem and a leading cause of chronic liver disease around the world, nearly 200 international hepatitis experts have taken an important step in escalating the introduction of a new class of targeted therapies for HCV – direct-acting antivirals.

15 Dec 2010

HRSA ranks UCLA's heart transplant program as best in the U.S.

A new survey by an agency of the U.S. Department of Health and Human Resources has recognized the heart transplant program at Ronald Reagan UCLA Medical Center as the nation's best.

13 Dec 2010

Research shows anti-microbial medications lead to acute liver failure

New research shows that anti-microbial medications are a common cause of drug-induced liver injury (DILI) leading to acute liver failure (ALF), with women and minorities disproportionately affected.

1 Dec 2010

FDA approves Merit's phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres

The Food and Drug Administration (FDA) has approved Merit Medical Systems, Inc.'s phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere™ Microspheres (hqTACE) for delivery of doxorubicin. The clinical trial will involve U.S. and international interventional radiologists who treat patients with localized, unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.

29 Nov 2010

Baylor Health Care System receives $20 million to benefit transplantation initiatives

Baylor Health Care System Foundation announces that Annette C. and Harold C. Simmons have pledged $20 million to benefit transplantation initiatives within Baylor Health Care System. In recognition of this transformational gift, Baylor will rename the institute the Annette C. and Harold C. Simmons Transplant Institute.

29 Nov 2010

Vertex submits NDA for telaprevir for treating hepatitis C

Vertex Pharmaceuticals Incorporated announced that it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for telaprevir, Vertex's investigational treatment for people with hepatitis C.

23 Nov 2010

New report highlights need for improved safety measures in organ procurement travel

The transplant community was largely unaware of sub-standard transportation practices for donor organs until a number of fatal air crashes took the lives of transplant personnel, calling attention to procurement aviation safety.

19 Nov 2010

13-hour lifesaving heart/liver transplant performed on pulmonary atresia patient

A 28-year old man from Georgia, David Krech, is recovering from a rare, lifesaving heart/liver transplant on October 15 at the University of Maryland Medical Center. The 13-hour operation followed a five-month journey as he awaited a suitable heart and liver donor.

17 Nov 2010

HealthGrades evaluates nation's top-performing hospitals in organ transplantation

HealthGrades, the nation's leading independent ratings organization, today made available to organ transplant patients a list of those hospitals with the best track record for survival and chances of receiving a donor organ. HealthGrades annual evaluation of the nation's top-performing hospitals in organ transplantation includes clinical quality data, based on patient outcomes, for each of the 210 adult acute care hospitals that perform transplants.

17 Nov 2010

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Children with hepatitis C fare decidedly better with a supercharged combination of two antiviral drugs than with the usual and standard single-drug regimen, according to research led by investigators at the Johns Hopkins Children Center.

11 Nov 2010

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has been notified that it has been awarded approximately $489,000 total in two federal grants under the Qualifying Therapeutic Discovery Project ("QTDP") Program.

2 Nov 2010

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.

1 Nov 2010

Race of donor may affect recurrent hepatitis C in patients after liver transplantation: Study

The race of liver donors may affect recurrent hepatitis C in patients after liver transplant, according to a study by Henry Ford Hospital. Patients receiving white cadaveric donor grafts had significantly more aggressive recurrent hepatitis C than those receiving grafts from African-American donors regardless of recipient race, says Matthew Moeller, M.D., gastroenterology fellow at Henry Ford Hospital and lead author of the study.

1 Nov 2010

Study determines long-term clinical outcome of patients posttransplant after anitviral therapy

Researchers from the University of Bari, Italy, concluded that treating patients after transplantation with antiviral therapy creates a sustained viral response (SVR) and protects them from liver-related deaths. The purpose of this study was to determine the long-term clinical outcomes of patients posttransplant who underwent antiviral therapy for recurrent hepatitis C virus (HCV) infection of the liver graft.

1 Nov 2010

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix Pharmaceuticals, Inc. today announced that the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010) will be an important venue for ongoing discussion of hepatic encephalopathy, or HE.

1 Nov 2010

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Tibotec Pharmaceuticals announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., USA. The data will be presented as part of a late-breaker oral presentation on Monday, November 1.

1 Nov 2010

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.

1 Nov 2010

Study finds impact of pre-transplant BMI on post liver transplant survival in pediatric population

A new study from the University of Washington reported obese children are at increased mortality risk in later years following primary liver transplantation (LT).

29 Oct 2010

Anti-enolase antibody may contribute to bile duct injury in biliary atresia: Research

Researchers at the University of Colorado School of Medicine and The Children's Hospital have taken a big step toward understanding what causes one of the most serious liver diseases in infants.

27 Oct 2010

Experts use multi-disciplinary approach to provide innovative care for children

Liver tumors affect more than 300 children in the United States each year and management of these children requires coordinated comprehensive care from experts in many disciplines. To answer this problem, Texas Children's Hospital and Baylor College of Medicine announced today the formation of a new Liver Tumor Center that brings together renowned specialists in all aspects of liver cancer who will utilize a multi-disciplinary approach to provide the most comprehensive and innovative care for children afflicted with these diseases.

15 Oct 2010

Liver Transplant News and Research

Further Reading

Researchers introduce new class of drugs for HCV patients

HRSA ranks UCLA's heart transplant program as best in the U.S.

Research shows anti-microbial medications lead to acute liver failure

FDA approves Merit's phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres

Baylor Health Care System receives $20 million to benefit transplantation initiatives

Vertex submits NDA for telaprevir for treating hepatitis C

New report highlights need for improved safety measures in organ procurement travel

13-hour lifesaving heart/liver transplant performed on pulmonary atresia patient

HealthGrades evaluates nation's top-performing hospitals in organ transplantation

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Race of donor may affect recurrent hepatitis C in patients after liver transplantation: Study

Study determines long-term clinical outcome of patients posttransplant after anitviral therapy

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Study finds impact of pre-transplant BMI on post liver transplant survival in pediatric population

Anti-enolase antibody may contribute to bile duct injury in biliary atresia: Research

Experts use multi-disciplinary approach to provide innovative care for children

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News